Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
As Tracky launches integrated health solution
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
Subscribe To Our Newsletter & Stay Updated
